Hannah Kyle

Hannah Kyle is an experienced professional in the field of analytical method development and R&D, currently serving as an Analytical Method Development Specialist at Iksuda Therapeutics since November 2023. Prior to this role, Hannah held the position of Senior Scientist at Abingdon Health plc from January 2023 to November 2023 and worked as a Senior R&D Scientist and Applications Scientist at Avacta from May 2015 to January 2023, contributing to the development of the Affimer non-antibody binding scaffold. Earlier experience includes a PhD position at the University of Leeds/AstraZeneca from June 2011 to May 2015, and an industrial traineeship at Pfizer from September 2009 to September 2010. Educational qualifications include a degree in Pharmacology from the University of Leeds (2007 - 2011) and prior schooling at Lancaster Girls Grammar School and Our Lady's Catholic College.